Equities

Haleon PLC

HLN:LSE

Haleon PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)329.15
  • Today's Change0.550 / 0.17%
  • Shares traded12.63m
  • 1 Year change-3.45%
  • Beta--
Data delayed at least 20 minutes, as of May 03 2024 12:26 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy5
Outperform6
Hold5
Underperform1
Sell0

Share price forecast

The 15 analysts offering 12 month price targets for HALEON PLC have a median target of 370.00, with a high estimate of 410.00 and a low estimate of 330.00. The median estimate represents a 12.60% increase from the last price of 328.60.
High24.8%410.00
Med12.6%370.00
Low0.4%330.00

Dividends

In 2023, Haleon PLC reported a dividend of 0.06 GBP, which represents a 150.00% increase over last year. The 17 analysts covering the company expect dividends of 0.06 GBP for the upcoming fiscal year, an increase of 3.33%.
Div growth (TTM)150.00%
More ▼

Earnings history & estimates

On May 01, 2024, HALEON PLC reported 1st quarter 2024 earnings of 5.17 per share. This result exceeded the 4.66 consensus of the 2 analysts covering the company and exceeded last year's 1st quarter results by 5.60%.
The next earnings announcement is expected on Aug 26, 2024.
Average growth rate+8.99%
HALEON PLC reported annual 2023 earnings of 17.30 per share on Feb 29, 2024.
Average growth rate-5.98%
More ▼

Revenue history & estimates

HALEON PLC had 1st quarter 2024 revenues of 2.92bn. This missed the 2.92bn consensus estimate of the 3 analysts following the company. This was 2.24% below the prior year's 1st quarter results.
Average growth rate-0.44%
HALEON PLC had revenues for the full year 2023 of 11.30bn. This was 4.09% above the prior year's results.
Average growth rate+4.09%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.